Therefore, not only p-AKT expression can be used for prognosis, but also, these findings may pave the way for further research into the efficacy of a new approach for treating DLBCL using inhibitors of the PI3K/AKT pathway [84]. Here, AKT1 is linked to diffuse large B-cell lymphoma.